Eli Lilly & Company recently announced that it will acquire Prevail Therapeutics in an $800 million pharmaceutical acquisition deal.
The acquisition agreement will establish a new modality for...
AstraZeneca recently acquired Boston-based rare disease specialist, Alexion Pharmaceuticals, in a $39 billion pharmaceutical acquisition deal.
Notably, the deal will be AstraZeneca’s...
Merck recently signed a $2.75 billion pharmaceutical acquisition deal to purchase all outstanding shares of VelosBio, subject to certain customary adjustments.
Clinical-stage biopharmaceutical...
Bayer recently announced a $4 billion pharma acquisition deal with Asklepios BioPharmaceutical (AskBio) to broaden its base in cell and gene therapy.
As part of the acquisition deal, Bayer...
Johnson & Johnson recently announced the completion of a $6.5 billion pharmaceutical acquisition deal involving biotechnology company Momenta Pharmaceuticals, Inc.
This announcement comes a...
The COVID-19 pandemic has substantially shaped the pharmaceutical and biopharmaceutical industry over the first half of 2020, and while some of the activity was predictable, other trends have surprised...
Johnson & Johnson recently announced that it signed a $6.5 billion pharma acquisition deal with Momenta Pharmaceuticals Inc., a company that discovers novel therapies for immune-mediated...
Sanofi recently announced that it will acquire biopharmaceutical company, Principia Biopharma Inc, in a pharma acquisition deal of $100 per share in cash.
Principia Biopharma focuses on developing...
Bristol Myers Squibb recently announced it acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million.
Under the definitive agreement, Bristol Myers Squibb will be...
A recent PwC insights analysis found that the pharmaceutical merger and acquisition activity saw a notable decline in the first half of 2020, but the potential for consolidation in specific sub-sectors...
Gilead Sciences recently announced that it will acquire 49.9 percent equity interest in Pionyr Immunotherapeutics Inc with exclusive option for $275 million.
Pionyr, a privately held company...
Eli Lilly Company and Junshi Biosciences recently entered into an agreement to co-develop COVID-19 antibody therapies for the prevention and treatment of the novel coronavirus.
For more coronavirus...
Mylan recently announced that the proposed pharmaceutical merger with Upjohn, a division of Pfizer, is delayed due to the COVID-19 pandemic.
For more coronavirus updates, visit our resource page,...
A PriceWaterhouseCoopers report predicts biotechnology firms will be “extremely active” in merger and acquisition activity and drive pharmaceutical firms’ activity in 2020.
Last year...
2020 will be another blockbuster year for life sciences mergers and acquisitions, according to a recent report from Ernst & Young Health Sciences and Wellness. And companies' interest in...
California-based manufacturers of next-generation DNA sequencing (NGS) technology platforms Illumina and Pacific Biosciences of California (PacBio) recently decided to terminate their $1.2-billion...
By the midway point of 2019, more than $200 billion had exchanged hands, exceeding previous years of $198 billion and $178 in 2018 and 2017, respectively. And the recent closing of Bristol-Myers Squibb...
